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In this article, we report familial cases of type 2 congenital erythrocytosis (ECYT2) in two siblings, a 2-year-old boy and his younger 
sister. Both patients were diagnosed based on laboratory findings including erythrocytosis, elevated hemoglobin levels, and hematocrit. 
Acquired erythrocytosis was excluded based on the clinical features and genetic analysis of JAK2/CALR/MPL genes. Next-generation 
sequencing was employed for older brother revealing NM_000551.4: c.598C>T, p.Arg200Trp homozygous variant in the VHL gene, the 
similar variant was detected in the younger sibling. Sequencing analysis confirmed the VHL c.598C>T heterozygous variant in both 
parents. To the best of our knowledge, these are the first confirmed cases of familial erythrocytosis type 2, also known as Chuvash type, 
in Poland.
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Introduction
Erythrocytosis may be caused by several factors, including congenital 
or acquired genetic defects and conditions resulting in abnormal 
erythropoietin (EPO) production, such as chronic obstructive 
pulmonary disease, high altitude exposure, and EPO producing 
tumors. Erythrocytosis can be divided into two major groups: primary 
erythrocytosis, with low levels of EPO in the serum, with an intrinsic 
defect in the erythroid lineage and secondary erythrocytosis, when EPO 
production is increased due to acquired condition or genetic defect. 
Both primary and secondary erythrocytoses are mostly acquired. 
Polycythemia vera is the most common type of acquired primary 
erythrocytosis and associated with a canonical pathogenic variant in 
the Janus Kinase 2 (JAK2) gene, namely c.1849G>T, p.Val617Phe 
(p.V617F) [1, 2].
Familial (congenital) erythrocytosis is a rare disease and may belong 
to a primary or secondary type. The underlying genetic defects may 
affect different genes but ultimately lead to the elevated levels of 
EPO or hypersensitivity of erythroid progenitors to EPO. In contrast 
to the primary erythrocytosis, secondary erythrocytosis can be caused 
by additional abnormalities related to cardiac, pulmonary, or renal 
dysfunction. In addition, changes in the anatomical structure of the liver 
and spleen may be observed [1, 3].
Familial erythrocytosis may result from pathogenic variants in the 
EPOR, VHL, EGLN1, EPAS1, or EPO genes. Five types of familial 
erythrocytosis (ECYT) have been defined, from ECYT 1 to ECYT 5 
depending on which one of these genes is defective (Tab. I) [4]. In 
addition, variants in hemoglobin (HBB) and bisphosphoglycerate 
mutase (BPGM) genes which increase oxygen affinity may cause 
erythrocytosis. ECYT1 is the only primary congenital erythrocytosis and 
is caused by gain-of-function in the EPOR gene encoding erythropoietin 
receptor. ECYT1 is characterized by low serum EPO levels in contrast 
to other familial erythrocytoses. On the other hand, ECYT 2-5 belongs 
to secondary erythrocytosis and is caused by defects in genes involved 
in oxygen sensing pathways or due to aberrant Hb variants with high 
oxygen affinity. This results in higher EPO production and serum levels 
[1, 3, 4].
Familial type 2 erythrocytosis (ECYT2), also known as Chuvash type 
polycythemia, has been described for the first time almost 20 years ago 
in Chuvashia, one of the republics in Russia, where it is endemic [5]. 
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Further studies revealed this type of erythrocytosis in the population 
of Ischia, Italian island, and also in other parts of the world [6, 7]. 
ECYT2 is an autosomal recessive form of erythrocytosis associated 
with the c.598C>T (p.Arg200Trp) homozygous variant in the 
von Hippel-Lindau gene (VHL) [5, 8, 9]. VHL gene is located on 
chromosome 3 and encodes VHL protein, which functions as an E3 
ubiquitin ligase for hypoxia inducible factor (HIF). In normoxia, HIF-2a 
subunit is hydroxylated by prolyl hydroxylase domain-containing 
protein 2 (PHD2) and becomes a target for ubiquitination and 
proteasomal degradation mediated by VHL. Mutated VHL mimics 
hypoxia condition when HIF-1a is stabilized, translocates to nucleus 
and forms with HIF-1b active transcription factor. This leads to 
upregulation of downstream target genes such as EPO, transferrin 
(TF), transferrin receptor (TFRC), vascular endothelial growth 
receptor A (VEGF), solute carrier family 2 member 1 (SLC2A1) and 
consequently to dysregulation of blood homeostasis (Fig. 1) [10–13]. 
Although homozygous mutation causing Chuvash erythrocytosis 
which has been associated with a higher risk of thrombosis, 
heterozygosity has been linked with some degree of protection 
against anemia [14]. This phenomenon may explain the prevalence 
of heterozygous alleles despite the higher mortality of homozygotes.
Here, we describe the clinical and genetic characteristics of two 
siblings who were diagnosed with ECYT2 after the exclusion of the 
most common acquired types of erythrocytosis and employing next-
generation sequencing (NGS).
Table I. Five major types of congenital erythrocytoses
Disease 
name Gene Protein Inheritance
ECYT1 EPOR EPOR (erythropoietin receptor) Dominant 
ECYT2 VHL VHL (von Hippel-Lindau) Recessive 
ECYT3 EGLN1 PHD2 (prolyl hydroxylase 
domain-containing protein 2)
Dominant 
ECYT4 EPAS1 HIF2a (hypoxia Inducible  
factor 2a)
Dominant 
ECYT5 EPO EPO (erythropoietin) Dominant
Figure 1. The role of the VHL in the pathogenesis of ECYT2 [2-column image] 
 
Fig. 1. The role of the VHL in the pathogenesis of ECYT2
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Material and methods
Blood was drawn after receiving written consent from patients’ 
parents according to institutional guidelines and in accordance with 
The Code of Ethics of the World Medical Association (Declaration 
of Helsinki), and patients’ material was kept anonymous. Genomic 
DNA was isolated using the QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. Targeted 
sequencing of patient #1 was performed using the SeqCap EZ Choice 
Library (Roche, Basel, Switzerland) covering coding sequences of 
193 genes implicated in hematological diseases (see Suppl. Data 1).
DNA library was prepared from 550 ng DNA using Kapa Library 
Preparation Kit for Illumina (Roche), multiplexed with others before 
solution-based capture (Roche NimbleGen), and sequenced on 
Illumina MiSeqFGx. The mean depth of coverage was 85.61x. The 
variant discovery was performed according to GATK best practices. 
Variants more frequent than 1% in public databases (1,000 genomes, 
NHLBI ESP, and gnomAD) and 5% in our internal database were 
discarded from further analysis. Five bioinformatics predictors 
were used to identify possible protein-damaging variants: CADD, 
FATHMM, SIFT, PolyPhen2, and Mutation Taster.
NM_000551.4:c.598C>T variant in patient #2 was revealed by 
direct Sanger sequencing. In the polymerase chain reaction 
(PCR), the 206 bp fragment of the VHL exon 3 was amplified 
using HotStarTaq Plus DNA Polymerase (Qiagen) and specific 
primers flanking codon 200: F-CAGGAGACTGGACATCGTCA and 
R-AAGGAAGGAACCAGTCCTGT. The PCR product was purified 
using Agencourt AMPure XP (Beckman Coulter, Brea, CA, USA) 
and sequenced on Genetic Analyzer 3500 using BigDye chemistry 
(Applied Biosystems, Foster City, CA, USA). Sanger sequencing 
was also used to confirm the VHL c.598C>T heterozygous variant 
in parents.
Results and discussion
Patient #1. A 2-year-old boy was referred to the Department of 
Paediatric Oncology and Haematology, State Hospital No 2 in 
Rzeszow (south-eastern region of Poland, historically known as 
Galicia) due to elevated red cell values from 24 months of age 
(Tab. II). The boy was born G1P1 at 35 weeks of gestation. The 
perinatal period was uncomplicated apart from severe jaundice. His 
family history is unremarkable-neither thromboembolic events nor 
spine hematomas and arterial hypotonia have occurred among close 
relatives. But the parents have reported distant kinship in the fifth 
generation back. Until his admission, the boy had been developing 
properly and had not any significant illness. Physical examination was 
unremarkable apart from erythema on the cheeks. Among others, 
high values of red cell parameters in peripheral blood morphology 
(RBC = 6.87 million/µl; Hb = 19.1 g/dL; Ht = 55.6%) were found. 
A bone marrow biopsy with trepanobiopsy was performed. The biopsy 
and myelogram obtained did not show features of a proliferative 
process or any other structural abnormalities within the red blood 
cell system. None of the canonical pathogenic variants in JAK2, 
CALR, and MPL genes was found. The EPO level was within the 
reference range. Furthermore, any significant deviations were found 
in biochemical tests. A chest X-ray and abdominal ultrasound did not 
show any pathological lesions.
Due to clinical uncertainty, diagnostics was expanded and 
NGS was performed. A homozygous variant in the VHL gene 
(NM_000551.4:c.598C>T, p.Arg200Trp) was detected which is 
typical for type 2 erythrocytosis also known as Chuvash polycythemia 
(Fig. 2A). NGS results were additionally confirmed with Sanger 
sequencing (Fig. 2B). Then, both parents were examined for the 
genetic status of the VHL variant and Sanger sequencing confirmed 
the VHL c.598C>T heterozygosity in both parents (Fig. 2B).
ECYT2 is characterized by elevated hemoglobin level and 
hematocrit together with normal or elevated levels of EPO, as well 
as normal oxygen affinity. Clinical manifestations of the disease 
are associated with elevated levels of red blood cells as well as 
increased circulating blood volume. In children, they may include 
hyperviscosity syndrome characterized by headaches and dizziness, 
fatigue, drowsiness, blurred vision, hearing impairment, paresthesia, 
and myalgia. Hypoxia and peripheral hypoperfusion are associated 
with erythrocytosis, which also increases thromboembolic risk [15]. 
At a later age, an increase in the incidence of strokes, heart attacks, 
and a paradoxically increased frequency of bleeding are often 
Table II. Laboratory results of blood morphology of patients #1 and #2 at the time of diagnosis, after 12 (or 4 for #2) months of 
observation and maximum values
Patient #1 Patient #2
Diagnosis After 12 months of observation Maximum values Diagnosis 
After 4 months of 
observation Maximum values
WBC/µl 7,540 7,740 9,700 14,570 9,850 17,630
Neutrophils/µl 3,580 3,180 4,080 6,860 3,290 6,860
Lymphocytes/µl 3,140 3,900 4,500 6,420 5,600 6,420
RBC/µl 6,810,000 6,320,000 6,870,000 7,330,000 6,560,000 7,330,000
Hb [g/dL] 18.7 12.7 19.1 20.3 18.1 20.3 
Ht [%] 55.4 41.7 55.5 58.4 52.6 58.4 
MCV [fL] 81.4 66.0 81.4 79.7 80.2 83.8 
MCH [pg] 27.4 20.1 27.9 27.7 34.4 35.1 
PLT/µl 227,000 519,000 519,000 382,000 305,000 415,000
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Fig. 2. VHL c.598C>T pathogenic variant detected by NGS and Sanger sequencing. (A) NGS results of patient #1 presented as 
a screenshot from the IGV software. Chromosomal coordinate, the total number of reads, and variant allele frequency (VAF) are 
provided in the box. (B) Screenshot from the FinchTV software showing the VHL c.598C>T variant detected by Sanger sequencing in 
patient #1 (confirmation of NGS results), in patient #2 and patients’ parents. The control sample represents the reference sequence 
without the variant c.598C>T
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observed. Other complications include hemangiomas and pulmonary 
hypertension also occur [16]. Compared with other germline 
mutations that predispose to hemangioblastomas in the retina 
and central nervous system, renal tumors, pheochromocytoma, 
pancreatic tumors, and so on [17], VHL c.598C> T variant is not 
associated with tumor development [18].
In the described patient, phlebotomy was used as a treatment, 
which resulted in a temporary decrease in Hb and Ht. In total, eight 
treatments were performed over for 6 months. The boy remained 
in good general condition, no significant symptoms associated with 
erythrocytosis were observed, and his development was normal. After 
9 months of observation, peripheral blood red cell values gradually 
decreased (RBC = 6.32 million/µl; Hb = 12.7 g/dL; Ht = 41.7%). 
Currently, the boy is 4 years old and does not present any clinical 
symptoms of polycythemia.
Patient #2. A 9-month-old girl (G2P2 at 39 weeks of pregnancy, 
complicated by gestational diabetes), with a remarkable family 
history (her brother was diagnosed with a family type 2 erythrocytosis 
confirmed by a genetic test), was admitted to the clinic due to 
persistently elevated red blood cell values (RBC = 5.9 million/
µl; Hb = 16.8 g/dL; Ht = 47.2%), which had been observed from 
5 months of age. In the child’s previous medical history, recurrent 
mild upper respiratory tract infections and cow’s milk intolerance had 
also been found. At the time of admission, no abnormalities were 
found on physical examination. In peripheral blood morphology, 
similarly to her brother, increased red blood cell values were 
found (RBC = 7.33 million/µl; Hb = 20.3 g/dL; Ht = 58.4%). Further 
laboratory tests showed no other relevant abnormalities. Since NGS 
analysis in older brother revealed a pathogenic variant in VHL gene 
typical for familial erythrocytosis type 2, direct Sanger sequencing of 
the target amplicon was performed and revealed the presence of the 
same homozygous variant in the VHL gene (c.598C>T) as detected 
in her brother (Fig. 2B).
Treatment in the form of repeated courses of phlebotomy was 
scheduled. In total, 14 treatments have been performed for over 
4 months. The girl remains in good general condition, no significant 
symptoms associated with erythrocytosis were observed, and 
development was normal. Currently, the girl is 13 months old and 
does not present any pathological symptoms. Recently, peripheral 
blood red blood cell values remain elevated (RBC = 5.56 million/µl, 
Hb = 18.1 g/dL, Ht = 52.6%), so further phlebotomy treatments are 
necessary.
Conclusions
1. The course of familial type 2 erythrocytosis in infants and young 
children seems to be mild. The abnormal values of the red 
blood cell system in peripheral blood counts are the basis for 
diagnosis.
2. In the boy (patient #1) a spontaneous normalization of 
hemoglobin and hematocrit values was observed and currently, 
he does not require any treatment. Due to the small number of 
cases described in the literature, the duration of remission and 
the course of the disease are difficult to predict.
3. In such rare cases with an unclear cause of erythrocytosis, 
advanced genetic diagnostics, such as NGS, allows to reveal 
the underlying genetic defect and help to establish a proper 
diagnosis, choose therapeutic options, and assess the 
prognosis.
4. Phlebotomy in infants and young children appears to be a safe 
and effective procedure, without serious complications.
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